Findings seen in patients with hormone receptor-positive advanced breast cancer with relapse, progression during aromatase inhibitor treatment<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, June 5, 2023 (HealthDay News) — For patients with hormone receptor-positive advanced breast cancer with disease progression during or after treatment with an aromatase inhibitor, capivasertib-fulvestrant therapy results in significantly longer progression-free survival than fulvestrant alone, according to a study published in the June 1 issue of the New England Journal of Medicine<\/em>.<\/p>\n Nicholas C. Turner, M.D., Ph.D., from the Royal Marsden Hospital in London, and colleagues conducted a randomized trial involving premenopausal, perimenopausal, and postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who had a relapse or disease progression during or after aromatase inhibitor treatment, with or without previous cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitor therapy. A total of 708 participants were randomly assigned to receive capivasertib plus fulvestrant or placebo plus fulvestrant in a 1:1 ratio.<\/p>\n The researchers found that the median progression-free survival was 7.2 and 3.6 months in the capivasertib-fulvestrant group and the placebo-fulvestrant group, respectively, in the overall population (hazard ratio for progression or death, 0.60). The median progression-free survival was 7.3 and 3.1 months, respectively, in the AKT pathway-altered population (hazard ratio, 0.50). Rash and diarrhea were the most frequent adverse events of grade 3 or higher in patients receiving capivasertib-fulvestrant.<\/p>\n “Our findings suggest that capivasertib-fulvestrant treatment improved outcomes regardless of previous exposure to a CDK4\/6 inhibitor and reinforce the evidence that single-agent endocrine therapy has poor outcomes after receipt of a CDK4\/6 inhibitor,” the authors write.<\/p>\n The study was funded by AstraZeneca, the manufacturer of capivasertib. In addition, several authors disclosed ties to industry. <\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/sub><\/p>\n <\/i><\/p>\n